Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

BACKGROUND: Although lenalidomide is very effective in the treatment of anemia of lower risk myelodysplastic syndromes with 5q deletion (del 5q), concerns have been raised over the fact that this drug could trigger progression to acute myeloid leukemia in some patients. DESIGN AND METHODS: Ninety-fi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Adès, Lionel, Le Bras, Fabien, Sebert, Marie, Kelaidi, Charikleia, Lamy, Thierry, Dreyfus, François, Eclache, Virginie, Delaunay, Jacques, Bouscary, Didier, Visanica, Sorin, Turlure, Pascal, Bresler, Agnès Guerci, Cabrol, Marie-Paule, Banos, Anne, Blanc, Michel, Vey, Norbert, Delmer, Alain, Wattel, Eric, Chevret, Sylvie, Fenaux, Pierre
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2012
Assuntos:
Original Articles and Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3269480/
https://ncbi.nlm.nih.gov/pubmed/21993675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.045914
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados